Stage 3 chronic kidney disease (CKD) is estimated to affect over 30 million adults in the United States. Patients with advanced CKD, defined for our purposes as stage 4 and 5, will often have ongoing follow ups with a nephrologist. However, in CKD stage 3 (defined as eGFR 30-59mL/min) the PCP will often be at the helm of treatment. Managing CKD stage 3 can be complex, having a clinical pharmacist meet with your CKD patients prior to their office visit helps to prepare both the patient and you to have the most comprehensive and efficient visit possible.
It’s finally about to happen: The coverage gap or “donut hole” hated and often feared by many Medicare recipients is finally breathing its last as of Jan. 1. So, what does this mean for you?
Increasingly, we’re adding agents such as Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) and Glucagon-like peptide 1 agonists (GLP1) early on in treatment to mitigate risks for cardiovascular disease (CVD).
Primary care is…well…primary in delivering coordinated, patient-centered care. But the combination of primary and specialty clinicians along with those in palliative care can deliver another layer of support at a critical time in a patient’s life.
August 15, 2019 | By Kristen Engelen, PharmD Delivering comprehensive primary care as a CPC+ organization creates value. But it also takes a lot of work. RxLive and our national network of expert clinical pharmacists can help. We’re already working with some of your...
More than 5 million people in the U.S. have atrial fibrillation, leading to an increased risk of stroke and related heart problems. Here’s a cost/benefit analysis of some of the leading medication options for treating this prevalent condition and the role of PGx.